Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Opus NaturFit urostomy bag max 15-60mm
23965909641
|
Opus NaturFit urostomy bag max 15-60mm | Urostomy Bags | Stoma Appliances | No data available |
|
Orakay 1mg capsules
0906060Q0BCAAAE
|
Orakay | Phytomenadione | Nutrition and Blood | No data available |
|
Oral Impact oral powder 74g sachets citrus
090402000BBSWA0
|
Proprietary compound enteral nutrition | Enteral nutrition | Nutrition and Blood | No data available |
|
Oral Impact oral powder 74g sachets coffee
090402000BBSXA0
|
Proprietary compound enteral nutrition | Enteral nutrition | Nutrition and Blood | No data available |
|
Oral-B Anti-Plaque Alcohol-Free 0.05% mouth rinse
0905030G0BNACBC
|
Oral-B | Sodium fluoride | Nutrition and Blood | No data available |
|
Oraldene Icemint 0.1% mouthwash
1203040G0BBABAA
|
Oraldene | Hexetidine | Ear, Nose and Oropharynx | No data available |
|
Oramorph 100mg/5ml oral solution unit dose vials
0407020Q0BCAJCU
|
Oramorph | Morphine sulfate | Central Nervous System | No data available |
|
Oramorph 10mg/5ml oral solution unit dose vials
0407020Q0BCAHGB
|
Oramorph | Morphine sulfate | Central Nervous System | No data available |
|
Oramorph 30mg/5ml oral solution unit dose vials
0407020Q0BCAICT
|
Oramorph | Morphine sulfate | Central Nervous System | No data available |
|
Orange syrup
190607000AAANAN
|
Generic compound preparation BNF 1906070 | Other syrup preparations | Other Drugs and Preparations | No data available |
|
Orange tincture BP 2001
190606000AAAWAW
|
Generic compound preparation BNF 1906060 | Other tincture preparations | Other Drugs and Preparations | No data available |
|
Orap 2mg tablets
0402010R0BBAAAA
|
Orap | Pimozide | Central Nervous System | No data available |
|
Oraqix 25mg/25mg/g periodontal gel 1.7g cart with dispenser
1502010I0BFABAJ
|
Oraqix | Lidocaine | Anaesthesia | No data available |
|
Oraqix 25mg/25mg/g periodontal gel 1.7g cartridges
1502010I0BFAAAI
|
Oraqix | Lidocaine | Anaesthesia | No data available |
|
Orbifen Cold & Flu oral suspension
0309020AABCAAAB
|
Orbifen (Ibuprofen/pseudoephedrine hydrochloride) | Ibuprofen/pseudoephedrine hydrochloride | Respiratory System | No data available |
|
Orbifen For Children 100mg/5ml oral suspension
1001010J0CRAABH
|
Orbifen | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Orbifen For Children 100mg/5ml oral suspension 5ml sachets
1001010J0CRABBM
|
Orbifen | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Orciprenaline 10mg/5ml oral solution sugar free
0301012S0AAAGAG
|
Orcipren sulfate (Stimulant) | Orciprenaline sulfate | Respiratory System | No data available |
|
Orciprenaline 20mg tablets
0301012S0AAAFAF
|
Orcipren sulfate (Stimulant) | Orciprenaline sulfate | Respiratory System | No data available |
|
Oregon Grape root tincture
190606000BCVRA0
|
Proprietary compound preparation BNF 1906060 | Other tincture preparations | Other Drugs and Preparations | No data available |
|
Orelox 100mg tablets
0501021F0BBAAAA
|
Orelox | Cefpodoxime | Infections | No data available |
|
Orelox 40mg/5ml oral suspension paediatric
0501021F0BBABAB
|
Orelox | Cefpodoxime | Infections | No data available |
|
Orencia 125mg/1ml solution for injection pre-filled syringes
1001030V0BBABAB
|
Orencia | Abatacept | Musculoskeletal and Joint Diseases | No data available |
|
Orencia 250mg pdr for concentrate for inf vials
1001030V0BBAAAA
|
Orencia | Abatacept | Musculoskeletal and Joint Diseases | No data available |
|
Orencia 50mg/0.4ml inj pre-filled syringes
1001030V0BBAEAE
|
Orencia | Abatacept | Musculoskeletal and Joint Diseases | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.